$BBNX News

Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30

Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026

Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28

Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28

Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365

Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock

Beta Bionics - Interesting & Uncertain Times

Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?

Beta Bionics: Mint Clearance Marks The Shift Toward A Multi-Engine Growth Story

Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock

Beta Bionics Announces Proposed $125M Public Offering Of Common Stock

Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $23

Baird Maintains Neutral on Beta Bionics, Raises Price Target to $16

Beta Bionics’ insulin patch pump gets FDA nod

Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Beta Bionics Receives FDA Clearance For Its Mint Pump That Requires No Recharging And Integrates With Industry-Leading Continuous Glucose Monitors; Lowers FY26 Sales Guidance From $131M-$136M To $121M-$126M Reflecting Potential Revenue Deferral Impact Of Up To $10M In Q4 As New Prospective iLet Users Could Choose To Await The Launch Of Mint

William Blair Initiates Coverage On Beta Bionics with Market Perform Rating

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics